The estimated Net Worth of Harry Korman is at least 1.78 百万$ dollars as of 3 March 2024. Mr. Korman owns over 18,855 units of Mylan NV stock worth over 1,423,425$ and over the last 6 years he sold MYL stock worth over 0$. In addition, he makes 360,006$ as Non-Executive Independent Director at Mylan NV.
Harry has made over 7 trades of the Mylan NV stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 18,855 units of MYL stock worth 298,852$ on 3 March 2024.
The largest trade he's ever made was exercising 20,313 units of Mylan NV stock on 3 March 2023 worth over 321,961$. On average, Harry trades about 6,140 units every 152 days since 2018. As of 3 March 2024 he still owns at least 89,806 units of Mylan NV stock.
You can see the complete history of Mr. Korman stock trades at the bottom of the page.
Harry A. Korman serves as Non-Executive Independent Director of the Company. Mr. Korman held senior executive roles of increasing responsibility at Mylan Inc. and its subsidiaries from 1996 until July 2014. He served as Mylan Inc.’s global Chief Operating Officer from January 2012 until July 2014, after which he served in a consultant role with Mylan Inc. for one year. Prior to his service as Chief Operating Officer, he was the President, North America of Mylan Inc. commencing in October 2007. Mr. Korman also served as President of Mylan Pharmaceuticals Inc. from February 2005 to December 2009. During his time as an executive at Mylan, Mr. Korman was instrumental in identifying, evaluating and executing on significant commercial and business development opportunities in the United States and other countries, including the expansion of Mylan’s global generics businesses around the world, among many other important contributions to the Company. He joined Mylan in 1996 after the Company’s acquisition of UDL Laboratories, Inc. (n/k/a Mylan Institutional Inc.), and served as its president, among other prior responsibilities. Mr. Korman has served as a past director and vice chairman of the Generic Pharmaceutical Association, now known as the Association for Accessible Medicines. He also previously served as a director and vice chairman of the HDMA Foundation, which serves the healthcare industry by providing research and education focused on healthcare supply issues. As previously disclosed, Mr. Korman will serve as a director of Viatris upon the closing of the Combination. Mr. Korman’s qualifications to serve on Mylan’s Board include, among others, his extensive industry experience, his knowledge of healthcare systems and the U.S. and global commercial markets, and his leadership experience in the areas of global strategy, risk oversight, sales and marketing, commercial operations, supply chain, and business development, among other areas relevant and important to Mylan’s global business.
As the Non-Executive Independent Director of Mylan NV, the total compensation of Harry Korman at Mylan NV is 360,006$. There are 9 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of 18,509,300$.
Harry Korman is 62, he's been the Non-Executive Independent Director of Mylan NV since 2018. There are 6 older and 6 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.
Harry's mailing address filed with the SEC is 1000 MYLAN BOULEVARD, , CANONSBURG, PA, 15317.
Over the last 10 years, insiders at Mylan NV have traded over 1,861,785,794$ worth of Mylan NV stock and bought 202,008 units worth 5,767,632$ . The most active insiders traders include Laboratories Abbott Product...、Daniel Martin Jr Gallagher、Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of 5,605,891$. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth 149,624$.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Mylan NV executives and other stock owners filed with the SEC include: